CN112007144A - Application of Elabela polypeptide in preparation of antioxidant product - Google Patents
Application of Elabela polypeptide in preparation of antioxidant product Download PDFInfo
- Publication number
- CN112007144A CN112007144A CN202010854989.8A CN202010854989A CN112007144A CN 112007144 A CN112007144 A CN 112007144A CN 202010854989 A CN202010854989 A CN 202010854989A CN 112007144 A CN112007144 A CN 112007144A
- Authority
- CN
- China
- Prior art keywords
- elabela polypeptide
- aldosterone
- product
- nadph
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides an application of Elabela polypeptide in preparing an antioxidant product. The research of the invention finds that the Elabela polypeptide can inhibit a pathway of activating NADPH oxidase by a risk factor aldosterone (Aldo) or aldosterone analogue, reduce the activity of NADPH of a reactive oxygen species-producing enzyme, thereby reducing the generation of Reactive Oxygen Species (ROS) and inhibiting oxidative stress damage induced by the reactive oxygen species. Provides a new way for researching and developing novel antioxidant products.
Description
Technical Field
The invention belongs to the technical field of medicines. More particularly, relates to application of Elabela polypeptide in preparing antioxidant products.
Background
Skin aging is mainly started from the attack of free radicals on healthy cells, and for a long time, the symptoms of cell continuous damage, skin elasticity loss, dark skin color and the like can be caused. Anti-oxidation is a process that acts directly on free radicals or indirectly consumes substances that readily generate free radicals, preventing further reactions from occurring. The skin of the human body is continuously contacted with the outside, ultraviolet rays, radiation and air pollution are continuously infiltrated, free radicals are generated, collagen and elastic fibers of the skin are damaged, wrinkles are generated, and pigmentation and the like are caused. Oxidative stress refers to a series of stress reactions caused by imbalance of oxidative and antioxidant homeostasis of the body under the stimulation of internal and external factors and excessive accumulation of Reactive Oxygen Species (ROS), and the generation of excessive ROS can cause cell damage and induce various diseases. Therefore, the application of the antioxidant is particularly important in the healthy life of modern human beings.
At the present stage, the oxidative stress injury is not sufficiently protected, and a plurality of problems exist in related treatment methods, including the problems of large dosage, large toxic and side effects and the like. The Elabela polypeptide is an endogenous hormone synthesized by a human body, is expressed in kidney tissues, is a novel endogenous peptide ligand of a G protein-coupled receptor APJ, and plays an important role in various pathophysiological processes in an embryonic stage and an adult stage. Chinese patent publication No. CN110960671A provides application of Elabela polypeptide in preventing and/or treating chronic kidney injury diseases. However, the application of the Elabela polypeptide in antioxidation is not found.
Disclosure of Invention
The invention aims to provide application of an Elabela polypeptide in preparing an antioxidant product, and provides a new application of the Elabela polypeptide. Provides a new way for researching and developing novel natural antioxidant products.
The invention also aims to provide application of the Elabela polypeptide in preparing a product for relieving oxidative stress skin injury.
The invention also aims to provide an antioxidant skin care product prepared from the Elabela polypeptide.
The invention further aims to provide an antioxidant health product prepared from the Elabela polypeptide.
The above purpose of the invention is realized by the following technical scheme:
according to the invention, through the research of cell and in vivo animal experiments, the effect of Elabela polypeptide on the activity of NADPH (nicotinamide adenine dinucleotide) as a Reactive Oxygen Species (ROS) in renal tubular epithelial cells and the generation amount of the reactive oxygen species (NADH) is found, the ratio of NADP +/NADPH in the cells is obviously increased by treating the cells with aldosterone (Aldo), and the relative amount of ROS (nicotinamide adenine dinucleotide) as the Reactive Oxygen Species (ROS) in the cells is increased, and the treatment by adding the Elabela polypeptide can inhibit the pathway of activating NADPH oxidase by the aldosterone (Aldo) as a risk factor, reduce the activity of NADPH as the reactive oxygen species (NADPH), thereby reducing the generation of the Reactive Oxygen Species (ROS) and inhibiting oxidative stress injury induced. In a rat kidney injury model induced by aldosterone analogue deoxycorticosterone synergistic hypersalt (DOCA/salt), the activity of NADPH in the kidney and the expression quantity of four subunits of the NADPH are obviously increased; and the intrarenal high expression of Elabela polypeptide can obviously reduce the activity of NADPH induced by DOCA/salt and reduce the expression of four subunits of the NADPH. Namely, the experiment result shows that the Elabela polypeptide has the function of eliminating active oxygen, namely resisting oxidation.
The invention therefore claims the use of elabel polypeptides in the preparation of antioxidant products.
Preferably, the antioxidation is to inhibit activation of NADPH oxidase by aldosterone or an aldosterone analogue.
Preferably, the oxidation is inhibition of NADPH oxidase activity.
Preferably, the oxidation resistance is to reduce the generation of active oxygen. The generation of active oxygen is induced by aldosterone.
Preferably, the antioxidant product comprises an antioxidant medicine, a health product or a daily chemical product. Can be made into various dosage forms, such as powder, granule, capsule, tablet, powder, solution, emulsion or suspension.
The invention also claims application of the Elabela polypeptide in preparing a product for relieving oxidative stress skin injury.
Preferably, the oxidative stress skin damage is oxidative stress damage induced by activation of NADPH oxidase by aldosterone.
The invention also claims an antioxidant skin care product which comprises the Elabela polypeptide and acceptable substrates and auxiliary materials in the skin care product. The skin care products include face masks, eye creams, face creams, essences, face cleansers, skin lotions, sun blocks, and the like.
The invention also provides an antioxidant health product which comprises the Elabela polypeptide and pharmaceutically acceptable auxiliary materials.
The invention has the following beneficial effects:
the invention provides a novel application of Elabela polypeptide in antioxidation, wherein the Elabela polypeptide can inhibit a pathway of activating NADPH oxidase by a risk factor aldosterone (Aldo), inhibit the activity of NADPH of a reactive oxygen species-producing enzyme, thereby reducing the generation of Reactive Oxygen Species (ROS) and inhibiting oxidative stress damage induced by the reactive oxygen species. And the Elabela polypeptide is an endogenous hormone synthesized by the human body, is expressed in kidney tissues, hardly influences the activity of cells and has no toxicity. Provides a new way for researching and developing novel antioxidant products.
Drawings
FIG. 1 is a graph showing the effect of different treatment groups on the intracellular NADP +/NADPH ratio in example 1;
FIG. 2 is a graph showing the effect of different treatments on the amount of active oxygen produced in example 2;
FIG. 3 is the effect of different treatment groups on the intracellular NADP +/NADPH ratio in example 3;
FIG. 4 is the effect of the different treatment groups on the relative expression levels of the 4 subunits (P47, P22, gp91 and P67) of the intracellular NADPH enzyme in example 4.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
The Elabela polypeptide is an endogenous hormone synthesized by a human body, is mainly expressed in a kidney tissue, and has an amino acid sequence as follows: EKSVNFPRRRKLYRHNCFRRRCISLHSRVPFP are provided.
Example 1 Elabela polypeptide inhibits the Activity of aldosterone-activated NADPH enzymes
1. Experimental methods
Human tubular epithelial cells HK2 were plated in 6-well plates and cultured in DMEM-F12 medium (containing 10% serum and 1% double antibody) at 37 ℃ in a incubator to 70%.
Cell treatment was divided into 4 groups, respectively control (Ctrl): blank control, without any treatment;
aldosterone treatment group (Aldo): 0.1 μ M aldosterone for 24 hours;
elabela polypeptide treatment group (ELA): 1nM of Elabela polypeptide for 24 hours;
aldosterone + elabala polypeptide treatment group (Aldo + E peptides): after one hour of 1nM treatment with Elabela polypeptide, 0.1. mu.M aldosterone was added and treatment continued for 24 hours.
After 24 hours of treatment according to the groups, cells were collected. The relative amount of NADP +/NADPH in the cells was determined using a commercial NADPH activity assay kit.
2. Results of the experiment
As shown in FIG. 1, aldosterone significantly increased the intracellular NADP +/NADPH ratio compared to the control group, while Elabela polypeptide significantly reduced this effect of aldosterone. The effect of NADP +/NADPH was not significant for the group to which only Elabela polypeptide was added. This result indicates that elabel polypeptides can inhibit the activity of the reactive oxygen species-producing enzyme NADPH activated by the risk factor aldosterone (Aldo).
Example 2 inhibition of aldosterone-induced reactive oxygen species elevation by Elabela Polypeptides
1. Experimental methods
Human tubular epithelial cells HK2 were plated in 6-well plates and cultured in DMEM-F12 medium (containing 10% serum and 1% double antibody) at 37 degrees to 70%.
Cell treatments were divided into 4 groups, control (Ctrl), aldosterone treated (Aldo), elabel polypeptide treated (ELA), and aldosterone + elabel polypeptide treated (Aldo + E peptide), respectively. According to the groups, 1nM of Elabela polypeptide was treated for one hour, then 0.1. mu.M aldosterone was added to the corresponding group of cells, and after 24 hours of treatment, the cells were harvested. The relative amount of reactive oxygen species in the cells was determined using a commercial reactive oxygen species detection kit.
2. Results of the experiment
As shown in fig. 2, aldosterone significantly increased the relative amount of reactive oxygen species ROS in cells compared to the control group, while elabel polypeptides significantly reduced this effect of aldosterone. The effect of the relative amount of ROS was not significant for the panel with elabel polypeptide alone. The Elabela polypeptide is shown to reduce the generation of active oxygen.
Example 3 inhibition of the activity of DOCA/salt-activated NADPH enzymes by Elabela Polypeptides
1. Experimental methods
18 SD male rats were taken and divided into three groups: control group (Ctrl), deoxycorticosterone synergistic high salt group (DOCA/salt), and DOCA/salt + Elabela polypeptide intrarenal high expression group (DOCA/salt-E peptide).
Wherein the control rats were given normal feed and tap water;
deoxycorticosterone in combination with high salt group (DOCA/salt) rats were treated for 3 weeks by subcutaneously implanting deoxycorticosterone capsules (150mg/rat) while adding 1% NaCl to drinking water;
deoxycorticosterone in combination with the high salt group + Elabela polypeptide high expression in the kidney (DOCA/salt-E peptide) was treated for 3 weeks by intrarenal transfection of an Elabela polypeptide high expression vector followed by subcutaneous implantation of deoxycorticosterone capsules (150mg/rat) with 1% NACl in drinking water.
Three weeks after animal treatment, kidney tissue was taken, total cell contents were extracted, and intracellular relative amounts of NADP +/NADPH were measured using a commercial NADPH activity assay kit.
2. Results of the experiment
As shown in FIG. 3, DOCA/salt significantly increased the NADP +/NADPH ratio in renal tissue cells compared to the control group, while Elabela polypeptide significantly reduced this effect of DOCA/salt. This result indicates that elabel polypeptides inhibit the activity of NADPH, a reactive oxygen species, in rat kidney tissue activated by DOCA/salt.
Example 4 inhibition of DOCA/salt-activated NADPH enzymatic Activity by Elabela Polypeptides
1. Experimental methods
Animal experiments in example 3, kidney tissue was collected, total RNA was extracted, and the relative expression levels of 4 subunits constituting NADPH were determined by real-time fluorescent quantitative PCR.
2. Results of the experiment
As shown in FIG. 4, DOCA/salt significantly increased the relative expression of 4 subunits of NADPH enzyme (P47, P22, gp91 and P67) in renal tissue cells compared to the control group, while Elabela polypeptide significantly reduced the effect of DOCA/salt. This result further indicates that elabel polypeptides inhibit the activity of NADPH, a reactive oxygen species, in rat kidney tissue activated by DOCA/salt.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
- Application of Elabela polypeptide in preparing an antioxidant product.
- 2. The use according to claim 1, wherein the antioxidation is to inhibit activation of NADPH oxidase by aldosterone or an aldosterone analogue.
- 3. The use according to claim 1, wherein the oxidation resistance is the inhibition of NADPH oxidase activity.
- 4. The use according to claim 1, wherein the oxidation resistance is to reduce the generation of active oxygen.
- 5. The use of claim 1, wherein the product comprises a pharmaceutical, nutraceutical, or daily chemical product.
- Application of Elabela polypeptide in preparing a product for relieving oxidative stress skin injury.
- 7. The use according to claim 6, characterized in that said oxidative stress skin lesions are oxidative stress lesions induced by activation of NADPH oxidase by aldosterone.
- 8. An antioxidant skin care product is characterized by comprising Elabela polypeptide, and acceptable matrix and auxiliary materials in the skin care product.
- 9. The skin care product of claim 8, wherein the skin care product comprises a mask, an eye cream, or a face cream. Essence, face cleansing cream, toner and sunscreen cream.
- 10. An antioxidant health product is characterized by comprising Elabela polypeptide and pharmaceutically acceptable auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010854989.8A CN112007144A (en) | 2020-08-24 | 2020-08-24 | Application of Elabela polypeptide in preparation of antioxidant product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010854989.8A CN112007144A (en) | 2020-08-24 | 2020-08-24 | Application of Elabela polypeptide in preparation of antioxidant product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112007144A true CN112007144A (en) | 2020-12-01 |
Family
ID=73505591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010854989.8A Pending CN112007144A (en) | 2020-08-24 | 2020-08-24 | Application of Elabela polypeptide in preparation of antioxidant product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112007144A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617368A (en) * | 2023-05-30 | 2023-08-22 | 杭州师范大学 | Application of Elabela in vascular endothelial cell aging resistance |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109609539A (en) * | 2018-12-25 | 2019-04-12 | 新乡医学院 | A method of preparing ELABELA polypeptide from recombinant yeast pichia pastoris |
| CN110960671A (en) * | 2019-12-25 | 2020-04-07 | 广州中医药大学(广州中医药研究院) | New application of Elabela polypeptide and medicine thereof |
-
2020
- 2020-08-24 CN CN202010854989.8A patent/CN112007144A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109609539A (en) * | 2018-12-25 | 2019-04-12 | 新乡医学院 | A method of preparing ELABELA polypeptide from recombinant yeast pichia pastoris |
| CN110960671A (en) * | 2019-12-25 | 2020-04-07 | 广州中医药大学(广州中医药研究院) | New application of Elabela polypeptide and medicine thereof |
Non-Patent Citations (2)
| Title |
|---|
| ZHIDA CHEN 等: "ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway", 《CELL DEATH DIS》 * |
| 周璐 等: "子痫前期孕妇尿液中ELABELA水平变化及意义", 《中国现代药物应用》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617368A (en) * | 2023-05-30 | 2023-08-22 | 杭州师范大学 | Application of Elabela in vascular endothelial cell aging resistance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simone et al. | Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? | |
| JP6215364B2 (en) | MC-1R, MC-2R, and μ opioid receptor modulation | |
| US8906425B2 (en) | Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers | |
| CN103687940B (en) | For the processing method of mescenchymal stem cell and the application in oxidative stress treating correlative diseases thereof | |
| CN101410089B (en) | Cosmetic active ingredient composed of arginine ferrulate and a microalgae extract and its uses | |
| EP3978020A1 (en) | Skin composition | |
| WO2019227034A1 (en) | Therapeutic compositions for enhanced healing of wounds and scars | |
| US20190111108A1 (en) | Composition Including GDF11 and Use Thereof | |
| US20090054346A1 (en) | Elastin production-enhancing agents | |
| KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| US5057320A (en) | Means and method for increasing skin respiration | |
| KR101501328B1 (en) | Skin care Composition | |
| US20220193147A1 (en) | Anti-aging Composition Containing Akkermansia Muciniphila as Active Ingredient and a Method for Preventing Aging Using Thereof | |
| CN112007144A (en) | Application of Elabela polypeptide in preparation of antioxidant product | |
| CN110590912A (en) | Novel antioxidant active polypeptide OA-VI12 as well as preparation method and application thereof | |
| CN111732634B (en) | Application of earthworm active peptide for inhibiting melanocyte proliferation in preparation of medicines or cosmetics | |
| KR101806992B1 (en) | Cosmetic compositions for preventing skin cell death comprising extracts of fermented red ginseng | |
| US20150182597A1 (en) | Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity | |
| CN110872568B (en) | Composition for preventing or improving aging comprising Bacillus pumilus strain or culture solution thereof | |
| KR20210045695A (en) | Composition for Inducing Autophagy Activity Comprising 2-Fucosyllactose | |
| KR20200054590A (en) | Composition for improving skin barrier comprising precipitation of fermented rice bran as active ingredient | |
| KR102475936B1 (en) | A cosmetic composition comprising yeast expressing peptide LL-37 | |
| KR20210105234A (en) | The Development of Cosmeceutical Products for Whitening and Anti-wrinkle Cosmetic Agent by using bracken(Pteridium aquilinum) bio -conversion substance | |
| JP2005350435A (en) | Synthesis of loxl (lysyl oxidase-like) isoform for stimulating formation of elastic fiber and stimulation of activity | |
| CN111909960B (en) | Screening method for use proportion of peptide and/or protein composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |